Martin Carlsson

In a real-world European cohort of 16,940 adults receiving semaglutide alongside comprehensive digital obesity care, oral and injectable treatment produced comparable 18-month outcomes. Mean body weight loss reached 18.0% with oral semaglutide and 18.5% with injectable semaglutide, with similar improvements in central adiposity and metabolic markers.

In a real-world cohort of over 40,000 people living with obesity, digital care engaged patients across all socioeconomic groups, including low- and middle-income populations. However, affordability emerged as the primary driver of treatment discontinuation, with economic barriers disproportionately limiting long-term access and continuity of care.

At Nordic Obesity Meeting 2026 (NOM2026) in Stockholm, Yazen Presented New Real-World Data demonstrating how Digital, Personalised Obesity Care can Improve Long-Term Treatment Outcomes.

‍

Obesity in men extends beyond physical health—it intertwines with psychological and societal pressures that shape behavior, self-image, and overall wellbeing.

Obesity significantly impacts men’s hormonal health — particularly testosterone — increasing risks of fatigue, weight gain, and chronic disease; understanding this connection is key to effective treatment and long-term wellbeing.

Excess weight affects men’s physical, hormonal, and mental health in complex ways—understanding these challenges is key to achieving sustainable weight loss and improved wellbeing.

Obesity in men is more than a weight issue — it’s a complex medical condition with far-reaching health risks. From heart disease and liver problems to hormonal and psychological effects, understanding these connections is key to effective prevention and management.

Many men think major weight loss is needed for real results, but even small reductions can greatly boost heart health, hormones, and overall wellbeing.

At ECO 2025 in Malaga, Yazen unveiled digital solutions and personalised strategies that are revolutionising obesity management and enhancing outcomes.